Stock Watch: Cytokinetics – From Certain Villain To Possible Hero
But Positive Phase III Study May Not Result In Big Pharma Acquisition
Investors’ euphoria on Cytokinetics’ positive Phase III study may be tempered by its high debt, pass-through royalties, entrenched competition and the FTC in the terms of any transaction.
